Dapagliflozin prevents contrast-induced acute kidney injury in rats via Nrf2/HO-1-mediated inhibition of NLRP3 inflammation and tubular apoptosis Short Title: Dapagliflozin prevents CI-AKI via Nrf2/HO-1
This study demonstrates that dapagliflozin prevents contrast-induced acute kidney injury in rats by activating the Nrf2/HO-1 antioxidant pathway as a central hub to synergistically inhibit NLRP3-mediated inflammation and tubular apoptosis, a mechanism that is essential for its renoprotective effects and superior to conventional hydration.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of patients undergo medical imaging procedures that rely on special dyes to make blood vessels and organs visible on X-rays and scans. These dyes, known as contrast media, are essential for diagnosing heart conditions and blockages, but they carry a hidden risk. For some patients, particularly those with existing kidney issues or diabetes, the dye can cause sudden and severe kidney failure, a condition called contrast-induced acute kidney injury. This complication often leads to longer hospital stays, higher medical costs, and a greater chance of long-term damage or death. Currently, the only widely recommended way to prevent this injury is to give patients large amounts of intravenous fluids before the scan, a method that works by flushing the dye through the system but does not actively protect the kidney cells from the chemical stress the dye causes. Scientists have long searched for a medication that could do more than just flush the system, one that could actively shield the kidneys from the damage before it begins.
In a new study, researchers investigated whether a drug called dapagliflozin, originally designed to help people with diabetes manage their blood sugar, could serve as this protective shield. The team worked with thirty-six rats, dividing them into groups to test different scenarios. Some rats received the dye alone to induce kidney injury, while others received the dye after being treated with dapagliflozin. To ensure the drug was working through a specific biological pathway, the researchers also used a group of rats where they blocked a key protective enzyme in the body before giving the drug. They compared the results of the drug-treated rats against those who received only the standard fluid treatment and those who received nothing. The goal was to see if the drug could stop the kidney cells from dying and reduce the inflammation that follows the injection of the dye.
The results showed that the rats treated with dapagliflozin before the dye injection suffered far less kidney damage than those who received only fluids. The drug-treated animals maintained much better kidney function, with lower levels of waste products in their blood and a higher ability to filter fluids. When the researchers examined the kidney tissue under a microscope, they saw that the drug-treated rats had far fewer signs of cell death and inflammation compared to the injured group. The standard fluid treatment helped somewhat, but the drug provided a much stronger defense, preserving the structure of the kidney tubes that are usually destroyed by the dye. The study confirmed that the drug works by turning on a natural defense system inside the kidney cells that neutralizes harmful chemicals and stops the inflammatory signals that trigger cell death.
To understand exactly how this protection happened, the researchers traced the molecular signals inside the cells. They found that the drug activated a specific protein called Nrf2, which acts like a master switch for the body's antioxidant defenses. This switch turned on another protein, HO-1, which produces substances that calm oxidative stress, a type of cellular damage caused by the dye. The study demonstrated that this HO-1 protein is the central hub of the protection; when the researchers blocked HO-1 with a specific inhibitor, the drug stopped working entirely, and the rats suffered kidney injury just as badly as those who received no treatment. This proved that the drug's ability to protect the kidneys depends entirely on this specific pathway. Furthermore, the drug successfully stopped a chain reaction involving a protein called NLRP3, which normally triggers severe inflammation, and it prevented the activation of enzymes that cause cells to self-destruct.
The findings suggest that dapagliflozin offers a multi-layered defense against kidney injury that goes beyond simple hydration. By activating the Nrf2/HO-1 pathway, the drug simultaneously reduces oxidative stress, calms inflammation, and prevents the death of kidney cells. The researchers noted that while fluid therapy addresses the physical concentration of the dye, the drug targets the biological mechanisms that cause the cells to fail. Although this study was conducted in rats and not humans, the results provide a strong scientific basis for testing this drug in patients who are at high risk of kidney injury during medical imaging. The study concludes that this approach could offer a new, more effective way to prevent kidney damage in vulnerable patients, moving beyond the current standard of care to a strategy that actively protects the organ at a cellular level.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.